Literature DB >> 10419100

Tumor necrosis factor-alpha and ceramides in insulin resistance.

D N Brindley1, C N Wang, J Mei, J Xu, A N Hanna.   

Abstract

The present studies tested the hypothesis that some effects of tumor necrosis factor-alpha (TNF-alpha) are mediated by activation of sphingomyelinases and the production of ceramides. Differentiated 3T3-L1 adipocytes were incubated with short-chain ceramide analogs, (C2- and C6-ceramides: N-acetyl- and N-hexanoyl-sphingosines, respectively), and this treatment increased 2-deoxyglucose uptake in the absence of insulin progressively from 2-24 h. This effect was inhibited by blocking the activations of mitogen-activated protein kinase, phosphatidylinositol 3-kinase (PI 3-kinase), and ribosomal S6 kinase which mediated an increase in GLUT1 concentrations. Long-term increases in PI 3-kinase activity associated with insulin receptor substrate-1 (IRS-1) increased the proportion of GLUT1 and GLUT4 in plasma membranes. These events explain the increases in noninsulin-dependent glucose uptake and incorporation of this glucose into the fatty acid and glycerol moieties of triacylglycerol. The mechanisms by which TNF-alpha and ceramides increase PI 3-kinase activity were investigated further by using rat2 fibroblasts. Incubation for 20 min with TNF-alpha, bacterial sphingomyelinase, or C2-ceramides increased PI 3-kinase activity by about fivefold, and this effect depended upon a stimulation of tyrosine kinase activity and an increase in Ras-GTP. This demonstrates the existence of a novel signaling pathway for TNF-alpha that could contribute to the effects of this cytokine in stimulating basal glucose uptake. By contrast, treating the 3T3-L1 adipocytes for 2-24 h with C2-ceramide diminished insulin-stimulated glucose uptake by decreasing the insulin-induced translocation of GLUT1 and GLUT4 to plasma membranes. This inhibition was observed when there was no increase in basal glucose uptake, and it occurred downstream of PI 3-kinase. Our work provides further mechanisms whereby TNF-alpha and ceramides produce insulin resistance and decrease the effectiveness of insulin in stimulating glucose disposal from the blood. Conversely, TNF-alpha and ceramides increase the ability of adipocytes to take up glucose and store triacylglycerol in the absence of insulin.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10419100     DOI: 10.1007/BF02562240

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.646


  22 in total

1.  Sphingomyelinase and ceramide suppress insulin-induced tyrosine phosphorylation of the insulin receptor substrate-1.

Authors:  H Kanety; R Hemi; M Z Papa; A Karasik
Journal:  J Biol Chem       Date:  1996-04-26       Impact factor: 5.157

2.  A novel pathway for tumor necrosis factor-alpha and ceramide signaling involving sequential activation of tyrosine kinase, p21(ras), and phosphatidylinositol 3-kinase.

Authors:  A N Hanna; E Y Chan; J Xu; J C Stone; D N Brindley
Journal:  J Biol Chem       Date:  1999-04-30       Impact factor: 5.157

3.  The insulin-dependent biosynthesis of GLUT1 and GLUT3 glucose transporters in L6 muscle cells is mediated by distinct pathways. Roles of p21ras and pp70 S6 kinase.

Authors:  C Taha; Y Mitsumoto; Z Liu; E Y Skolnik; A Klip
Journal:  J Biol Chem       Date:  1995-10-20       Impact factor: 5.157

4.  Role of p21ras in insulin-stimulated glucose transport in 3T3-L1 adipocytes.

Authors:  S F Hausdorff; J V Frangioni; M J Birnbaum
Journal:  J Biol Chem       Date:  1994-08-26       Impact factor: 5.157

5.  Tumor necrosis factor enhances glucose uptake by peripheral tissues.

Authors:  D A Evans; D O Jacobs; D W Wilmore
Journal:  Am J Physiol       Date:  1989-11

6.  Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase.

Authors:  P Peraldi; G S Hotamisligil; W A Buurman; M F White; B M Spiegelman
Journal:  J Biol Chem       Date:  1996-05-31       Impact factor: 5.157

7.  Effect of tumor necrosis factor-alpha on insulin action in cultured rat skeletal muscle cells.

Authors:  N Begum; L Ragolia
Journal:  Endocrinology       Date:  1996-06       Impact factor: 4.736

8.  Differential regulation of GLUT1 and GLUT4 glucose transporters in skeletal muscle of a new model of type II diabetes. The obese SHR/N-cp rat.

Authors:  A Marette; C Atgié; Z Liu; L J Bukowiecki; A Klip
Journal:  Diabetes       Date:  1993-08       Impact factor: 9.461

9.  Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-alpha on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells.

Authors:  D Szalkowski; S White-Carrington; J Berger; B Zhang
Journal:  Endocrinology       Date:  1995-04       Impact factor: 4.736

Review 10.  Tumor necrosis factor alpha: a key component of the obesity-diabetes link.

Authors:  G S Hotamisligil; B M Spiegelman
Journal:  Diabetes       Date:  1994-11       Impact factor: 9.461

View more
  5 in total

Review 1.  RACking up ceramide-induced islet β-cell dysfunction.

Authors:  Anjaneyulu Kowluru; Renu A Kowluru
Journal:  Biochem Pharmacol       Date:  2018-04-30       Impact factor: 5.858

Review 2.  Potential mechanisms of muscle mitochondrial dysfunction in aging and obesity and cellular consequences.

Authors:  Emilie Chanséaume; Béatrice Morio
Journal:  Int J Mol Sci       Date:  2009-01-13       Impact factor: 6.208

Review 3.  Adipocyte Ceramides-The Nexus of Inflammation and Metabolic Disease.

Authors:  Bhagirath Chaurasia; Chad Lamar Talbot; Scott A Summers
Journal:  Front Immunol       Date:  2020-09-23       Impact factor: 7.561

Review 4.  IGF-IR in neuroprotection and brain tumors.

Authors:  Elisa Gualco; Jin Ying Wang; Luis Del Valle; Katarzyna Urbanska; Francesca Peruzzi; Kamel Khalili; Shohreh Amini; Krzysztof Reiss
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01

5.  Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance.

Authors:  Jacob M Haus; Sangeeta R Kashyap; Takhar Kasumov; Renliang Zhang; Karen R Kelly; Ralph A Defronzo; John P Kirwan
Journal:  Diabetes       Date:  2008-11-13       Impact factor: 9.461

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.